Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday ...

Novartis has lost its legal challenge against the Inflation Reduction Act on Friday, making it the sixth drugmaker rejected ...

Lykos Therapeutics said it had a “productive” meeting with the FDA to discuss a path forward for its recently rejected PTSD ...

Two central nervous system disorder biotechs laid off employees recently. New York gene therapy startup Apertura and Boston ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

The FDA on Friday approved Astellas’ treatment for a type of gastric cancer, marketed as Vyloy (zolbetuximab). The approval ...

Adi Hoess describes himself as someone who “likes to build” companies focused on “challenging technologies.” It’s fitting, ...

Pfizer has ended its trial of an SHP2 inhibitor that was being developed in cancer, the latest blow to the target after ...

Merck’s experimental antibody for RSV reduced infants’ risk of certain lower respiratory infections by 60.4% compared to ...

Josh Bilenker and Jeff Engelman's secretive startup Treeline Biosciences has another $421 million, according to a new SEC ...

Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...

Pfizer's RSV vaccine was 90% effective at preventing the most severe outcomes in the first-ever vaccination season, the ...